Encyclopedia of AIDS

Living Edition
| Editors: Thomas J. Hope, Douglas Richman, Mario Stevenson

Antiretroviral Medications, Adult Care, and Treatment

Living reference work entry
DOI: https://doi.org/10.1007/978-1-4614-9610-6_166-1


Antiretroviral medication(s): There are currently five main groups of antiretroviral (ARV) medications used to treat HIV. They are called ARV medications because they act against the life cycle of the retrovirus HIV. The five groups are as follows (of note, they are categorized by how they interfere with the HIV life cycle with the sixth group/designation “multi-class combination products” containing different combinations of ARV medications from the main groups working against various components of the HIV life cycle):
  1. 1.

    Entry inhibitors: ARV medications in this class of ARVs effectively interfere with the receptor-mediated entry of the HIV virus into a cell. One subclass of entry inhibitors is the CCR5 antagonists; and the one medication approved for use currently in this subclass is maraviroc, with viroc standing for virus occupying. A new medication in this class, cenicriviroc, is currently in preclinical studies and may be available soon.

  2. 2.

    Fusion inhibitors: ARV...

This is a preview of subscription content, log in to check access.


  1. Aberg JA, Gallant JE, Ghanem KG, Emmanuel P, Zingman BS, Horberg MA. Primary care guidelines for the management of persons infected with HIV: 2013 update by the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis. 2014;58(1):1–10.CrossRefPubMedGoogle Scholar
  2. Boulware DR, Meya DB, Muzoora C, et al. Timing of antiretroviral therapy after diagnosis of cryptococcal meningitis. N Engl J Med. 2014;370(26):2487–98. Available at http://www.ncbi.nlm.nih.gov/pubmed/24963568.CrossRefPubMedPubMedCentralGoogle Scholar
  3. Bwakura-Dangarembizi M, Kendall L, Bakeera-Kitaka S, Nahirya-Ntege P, Keishanyu R, Nathoo K, the Antiretroviral Research for Watoto (ARROW) Trial Team. A randomized trial of stopping or continuing co-trimoxazole in HIV-infected children. N Engl J Med. 2014;370:41–53.CrossRefPubMedPubMedCentralGoogle Scholar
  4. Campbell JD, Moore D, Degerman R, Kaharuza F, Were W, Muramuzi E, et al. HIV-infected Ugandan adults taking antiretroviral therapy with CD4 counts >200 cells/μL who discontinue co-trimoxazole prophylaxis have increased risk of malaria and diarrhea. Clin Infect Dis. 2012;54:1204–11.CrossRefPubMedGoogle Scholar
  5. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365(6):493–505. Available at http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=21767103.CrossRefPubMedPubMedCentralGoogle Scholar
  6. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. Recommendations for a public health approach – Second edition; released/published http://www.who.int/hiv/pub/arv/arv-2016/en/. Updated/released June 2016.
  7. Grant RM, Lama JR, Anderson PL, iPrEx Study Team, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363(27):2587–99. PMID: 21091279.CrossRefPubMedPubMedCentralGoogle Scholar
  8. Inker LA, Schmid CH, Tighiouart H, for the CKD-EPI Investigators, et al. Estimating glomerular filtration rate from serum creatinine and cystatin C. N Engl J Med. 2012;367:20–9. PMID: 22762315.CrossRefPubMedPubMedCentralGoogle Scholar
  9. INSIGHT START Study Group, Lundgren JD, Babiker AG, et al. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med. 2015;373(9):795–807. Available at http://www.ncbi.nlm.nih.gov/pubmed/26192873.CrossRefGoogle Scholar
  10. Makadzange AT, Ndhlovu CE, Takarinda K, et al. Early versus delayed initiation of antiretroviral therapy for concurrent HIV infection and cryptococcal meningitis in sub-Saharan Africa. Clin Infect Dis. 2010;50(11):1532–8. Available at http://www.ncbi.nlm.nih.gov/pubmed/20415574.CrossRefPubMedGoogle Scholar
  11. Mallal S, Phillips E, Carosi G, et al. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med. 2008;358(6):568–79.CrossRefPubMedGoogle Scholar
  12. Martin AM, Almeida CA, Cameron P, et al. Immune responses to abacavir in antigen-presenting cells from hypersensitive patients. AIDS. 2007;21(10):1233–44.CrossRefPubMedGoogle Scholar
  13. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Developed by the DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents – A Working Group of the Office of AIDS Research Advisory Council (OARAC) and last updated July 14th, 2016. Available at http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed 22 Aug 2017.
  14. Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. Available at http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf. Accessed 22 Aug 2017; pp 160–170.
  15. Polyak CS, Yuhas K, Singa B, Khaemba M, Watson J, Richardson B et al. CTX prophylaxis discontinuation among ART treated adults: a randomized non-inferiority trial. In: Twenty-first conference on retroviruses and opportunistic infections (CROI), Boston, 3–6 Mar 2014 [Abstract 98]. http://www.croiconference.org/sites/default/files/abstracts/98.pdf. Accessed 11 Nov 2015.
  16. TEMPRANO ANRS Study Group, Danel C, Moh R, et al. A trial of early antiretrovirals and isoniazid preventive therapy in Africa. N Engl J Med. 2015;373(9):808–22. Available at http://www.ncbi.nlm.nih.gov/pubmed/26193126.9.CrossRefGoogle Scholar
  17. Thigpen MC, Rose CE, Paxton LA. Antiretroviral preexposure prophylaxis for HIV prevention. N Engl J Med. 2013;368(1):82–3.CrossRefPubMedGoogle Scholar
  18. UNAIDS fact sheet (released July 2017). Available at: http://www.unaids.org/sites/default/files/media_asset/UNAIDS_FactSheet_en.pdf.
  19. Wester CW, Bussmann H, Koethe J, Moffat C, Vermund SH, Essex M, Marlink RG. Combination antiretroviral therapy in sub-Saharan Africa: lessons from Botswana and future challenges. HIV Ther. 2009;3(5):501–26.CrossRefPubMedPubMedCentralGoogle Scholar
  20. Zolopa A, Andersen J, Powderly W, et al. Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: a multicenter randomized strategy trial. PLoS One. 2009;4(5):e5575. Available at http://www.ncbi.nlm.nih.gov/pubmed/19440326.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media LLC 2017

Authors and Affiliations

  1. 1.Vanderbilt Institute for Global Health (VIGH)Vanderbilt University School of MedicineNashvilleUSA

Section editors and affiliations

  • Sten Vermund
    • 1
  1. 1.Anna M.R. Lauder Professor of Public HealthYale School of Public HealthNew HavenUSA